Skip to main content
main-content
Erschienen in: Die Innere Medizin 2/2022

28.01.2022 | Nebenwirkungen | Schwerpunkt: Biologika in der Inneren Medizin

Was muss der Internist bei Patienten unter Biologikabehandlung beachten?

Infektionen und Autoimmunphänomene

verfasst von: Prof. Dr. Thomas Zander, Michael Hallek

Erschienen in: Die Innere Medizin | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Biologika zur Beeinflussung des Immunsystems spielen in der Behandlung von Autoimmun- und Tumorerkrankungen eine wichtige Rolle. Durch den Einsatz dieser nebenwirkungsarmen und gut wirksamen Therapeutika hat sich die Behandlung deutlich verbessert, sodass es zu einem längeren therapeutischen Einsatz kommt. Daher spielen Nebenwirkungen in der ärztlichen Betreuung auch außerhalb der Primärbehandlung eine immer größere Rolle. Durch die immunsuppressiven bzw. immunmodulierenden Biologika steigt das Risiko von Infektionen mit typischen Erregern vor allem der oberen Atemwege und des Urogenitaltrakts. Aber auch Infektionen mit selteneren Erregern wie Pilzen oder Mykobakterien treten vermehrt auf. Unter immunverstärkenden Biologika treten an den verschiedensten Organen Autoimmunphänomene auf, die zunächst durch Pausierung der Therapie oder aber durch eine immunsuppressive Therapie behandelt werden können.
Literatur
1.
Zurück zum Zitat Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP (2010) Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 39:425–441 PubMedCrossRef Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP (2010) Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 39:425–441 PubMedCrossRef
2.
Zurück zum Zitat Taylor PC, Quattrocchi E, Mallett S, Kurrasch R, Petersen J, Chang DJ (2011) Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 70:2119–2125 PubMedCrossRef Taylor PC, Quattrocchi E, Mallett S, Kurrasch R, Petersen J, Chang DJ (2011) Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 70:2119–2125 PubMedCrossRef
3.
Zurück zum Zitat Nogid A, Pham DQ (2006) Role of abatacept in the management of rheumatoid arthritis. Clin Ther 28:1764–1778 PubMedCrossRef Nogid A, Pham DQ (2006) Role of abatacept in the management of rheumatoid arthritis. Clin Ther 28:1764–1778 PubMedCrossRef
4.
Zurück zum Zitat Winthrop KL, Mariette X, Silva JT et al (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 24(Suppl 2):S21–S40 PubMedCrossRef Winthrop KL, Mariette X, Silva JT et al (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 24(Suppl 2):S21–S40 PubMedCrossRef
5.
Zurück zum Zitat Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723 PubMedPubMedCentralCrossRef Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723 PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532 PubMedCrossRef Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532 PubMedCrossRef
7.
Zurück zum Zitat Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330 PubMedCrossRef Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330 PubMedCrossRef
8.
Zurück zum Zitat Larkin J, Chiarion-Sileni V, Gonzalez R et al (2019) Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med 381:1535–1546 PubMedCrossRef Larkin J, Chiarion-Sileni V, Gonzalez R et al (2019) Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med 381:1535–1546 PubMedCrossRef
9.
Zurück zum Zitat Demlova R, Valik D, Obermannova R, ZdraZilova-Dubska L (2016) The safety of therapeutic monoclonal antibodies: implications for cancer therapy including immuno-checkpoint inhibitors. Physiol Res 65:S455–S462 PubMedCrossRef Demlova R, Valik D, Obermannova R, ZdraZilova-Dubska L (2016) The safety of therapeutic monoclonal antibodies: implications for cancer therapy including immuno-checkpoint inhibitors. Physiol Res 65:S455–S462 PubMedCrossRef
11.
Zurück zum Zitat Hay KA, Hanafi LA, Li D et al (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T‑cell therapy. Blood 130:2295–2306 PubMedPubMedCentralCrossRef Hay KA, Hanafi LA, Li D et al (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T‑cell therapy. Blood 130:2295–2306 PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Lee DW, Gardner R, Porter DL et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124:188–195 PubMedPubMedCentralCrossRef Lee DW, Gardner R, Porter DL et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124:188–195 PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Maggi E, Vultaggio A, Matucci A (2011) Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol 7:55–63 PubMedCrossRef Maggi E, Vultaggio A, Matucci A (2011) Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol 7:55–63 PubMedCrossRef
15.
Zurück zum Zitat Muraro A, Lemanske RF Jr., Castells M et al (2017) Precision medicine in allergic disease-food allergy, drug allergy, and anaphylaxis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. Allergy 72:1006–1021 PubMedCrossRef Muraro A, Lemanske RF Jr., Castells M et al (2017) Precision medicine in allergic disease-food allergy, drug allergy, and anaphylaxis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. Allergy 72:1006–1021 PubMedCrossRef
16.
Zurück zum Zitat Vultaggio A, Matucci A, Nencini F et al (2010) Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 65:657–661 PubMedCrossRef Vultaggio A, Matucci A, Nencini F et al (2010) Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 65:657–661 PubMedCrossRef
17.
Zurück zum Zitat Benucci M, Manfredi M, Saviola G, Baiardi P, Campi P (2009) Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-alpha blocking agents in rheumatoid arthritis. Clin Exp Rheumatol 27:333–336 PubMed Benucci M, Manfredi M, Saviola G, Baiardi P, Campi P (2009) Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-alpha blocking agents in rheumatoid arthritis. Clin Exp Rheumatol 27:333–336 PubMed
18.
Zurück zum Zitat Matucci A, Pratesi S, Petroni G et al (2013) Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. Clin Exp Allergy 43:659–664 PubMed Matucci A, Pratesi S, Petroni G et al (2013) Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. Clin Exp Allergy 43:659–664 PubMed
19.
Zurück zum Zitat Dupont B, Mariotte D, Clarisse B et al (2014) Risk factors associated with hypersensitivity reactions to cetuximab: anti-cetuximab IgE detection as screening test. Future Oncol 10:2133–2140 PubMedCrossRef Dupont B, Mariotte D, Clarisse B et al (2014) Risk factors associated with hypersensitivity reactions to cetuximab: anti-cetuximab IgE detection as screening test. Future Oncol 10:2133–2140 PubMedCrossRef
20.
Zurück zum Zitat Steinke JW, Platts-Mills TA, Commins SP (2015) The alpha-gal story: lessons learned from connecting the dots. J Allergy Clin Immunol 135:589–596 (quiz 597) PubMedPubMedCentralCrossRef Steinke JW, Platts-Mills TA, Commins SP (2015) The alpha-gal story: lessons learned from connecting the dots. J Allergy Clin Immunol 135:589–596 (quiz 597) PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Singh JA, Wells GA, Christensen R et al (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011:CD8794 PubMedCentral Singh JA, Wells GA, Christensen R et al (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011:CD8794 PubMedCentral
23.
Zurück zum Zitat Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A (2011) Effectiveness and safety of the interleukin 6‑receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 70:755–759 PubMedCrossRef Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A (2011) Effectiveness and safety of the interleukin 6‑receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 70:755–759 PubMedCrossRef
24.
Zurück zum Zitat Kaegi C, Wuest B, Schreiner J et al (2019) Systematic review of safety and efficacy of Rituximab in treating immune-mediated disorders. Front Immunol 10:1990 PubMedPubMedCentralCrossRef Kaegi C, Wuest B, Schreiner J et al (2019) Systematic review of safety and efficacy of Rituximab in treating immune-mediated disorders. Front Immunol 10:1990 PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Riedell P, Carson KR (2014) A drug safety evaluation of rituximab and risk of hepatitis B. Expert Opin Drug Saf 13:977–987 PubMedCrossRef Riedell P, Carson KR (2014) A drug safety evaluation of rituximab and risk of hepatitis B. Expert Opin Drug Saf 13:977–987 PubMedCrossRef
26.
Zurück zum Zitat Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ (2014) Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford) 53:1872–1885 CrossRef Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ (2014) Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford) 53:1872–1885 CrossRef
27.
Zurück zum Zitat Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP (2008) Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 83:181–194 PubMedCrossRef Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP (2008) Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 83:181–194 PubMedCrossRef
28.
Zurück zum Zitat Vallabhaneni S, Chiller TM (2016) Fungal infections and new biologic therapies. Curr Rheumatol Rep 18:29 PubMedCrossRef Vallabhaneni S, Chiller TM (2016) Fungal infections and new biologic therapies. Curr Rheumatol Rep 18:29 PubMedCrossRef
29.
Zurück zum Zitat Martins F, Sofiya L, Sykiotis GP et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16:563–580 PubMedCrossRef Martins F, Sofiya L, Sykiotis GP et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16:563–580 PubMedCrossRef
30.
31.
Zurück zum Zitat Collins LK, Chapman MS, Carter JB, Samie FH (2017) Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer 41:125–128 PubMedCrossRef Collins LK, Chapman MS, Carter JB, Samie FH (2017) Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer 41:125–128 PubMedCrossRef
32.
Zurück zum Zitat Hwang SJ, Carlos G, Chou S, Wakade D, Carlino MS, Fernandez-Penas P (2016) Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies. Melanoma Res 26:413–416 PubMedCrossRef Hwang SJ, Carlos G, Chou S, Wakade D, Carlino MS, Fernandez-Penas P (2016) Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies. Melanoma Res 26:413–416 PubMedCrossRef
33.
Zurück zum Zitat Puzanov I, Diab A, Abdallah K et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5:95 PubMedPubMedCentralCrossRef Puzanov I, Diab A, Abdallah K et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5:95 PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Morganstein DL, Lai Z, Spain L et al (2017) Thyroid abnormalities following the use of cytotoxic T‑lymphocyte antigen‑4 and programmed death receptor protein‑1 inhibitors in the treatment of melanoma. Clin Endocrinol (Oxf) 86:614–620 CrossRef Morganstein DL, Lai Z, Spain L et al (2017) Thyroid abnormalities following the use of cytotoxic T‑lymphocyte antigen‑4 and programmed death receptor protein‑1 inhibitors in the treatment of melanoma. Clin Endocrinol (Oxf) 86:614–620 CrossRef
35.
Zurück zum Zitat Osorio JC, Ni A, Chaft JE et al (2017) Antibody-mediated thyroid dysfunction during T‑cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28:583–589 PubMedCrossRef Osorio JC, Ni A, Chaft JE et al (2017) Antibody-mediated thyroid dysfunction during T‑cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28:583–589 PubMedCrossRef
36.
Zurück zum Zitat Wolchok JD, Chiarion-Sileni V, Gonzalez R et al (2017) Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med 377:1345–1356 PubMedPubMedCentralCrossRef Wolchok JD, Chiarion-Sileni V, Gonzalez R et al (2017) Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med 377:1345–1356 PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Torino F, Corsello SM, Salvatori R (2016) Endocrinological side-effects of immune checkpoint inhibitors. Curr Opin Oncol 28:278–287 PubMedCrossRef Torino F, Corsello SM, Salvatori R (2016) Endocrinological side-effects of immune checkpoint inhibitors. Curr Opin Oncol 28:278–287 PubMedCrossRef
38.
Zurück zum Zitat Barroso-Sousa R, Barry WT, Garrido-Castro AC et al (2018) Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 4:173–182 PubMedCrossRef Barroso-Sousa R, Barry WT, Garrido-Castro AC et al (2018) Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 4:173–182 PubMedCrossRef
39.
Zurück zum Zitat Haanen J, Carbonnel F, Robert C et al (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv119–iv142 PubMedCrossRef Haanen J, Carbonnel F, Robert C et al (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv119–iv142 PubMedCrossRef
40.
Zurück zum Zitat Gupta A, De Felice KM, Loftus EV Jr., Khanna S (2015) Systematic review: colitis associated with anti-CTLA‑4 therapy. Aliment Pharmacol Ther 42:406–417 PubMedCrossRef Gupta A, De Felice KM, Loftus EV Jr., Khanna S (2015) Systematic review: colitis associated with anti-CTLA‑4 therapy. Aliment Pharmacol Ther 42:406–417 PubMedCrossRef
41.
Zurück zum Zitat Naidoo J, Wang X, Woo KM et al (2017) Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol 35:709–717 PubMedCrossRef Naidoo J, Wang X, Woo KM et al (2017) Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol 35:709–717 PubMedCrossRef
Metadaten
Titel
Was muss der Internist bei Patienten unter Biologikabehandlung beachten?
Infektionen und Autoimmunphänomene
verfasst von
Prof. Dr. Thomas Zander
Michael Hallek
Publikationsdatum
28.01.2022

Weitere Artikel der Ausgabe 2/2022

Die Innere Medizin 2/2022 Zur Ausgabe

Mitteilungen des BDI

Mitteilungen des BDI

Neu im Fachgebiet Innere Medizin

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.